MRNA logo Moderna +
Moderna
+

Moderna Overview

Company: Moderna
CEO: Stéphane Bancel
Founded: 2010
Symbol: MRNA
Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
About

Moderna, a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs,luding infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities,luding AstraZeneca PLC, Merck & Co., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Metagenomi, the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, the company officially became Moderna in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Continue reading...

Moderna (MRNA)

  • Stock Price
  • Volume
57.02 -278.85 -83.02%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Moderna annual revenue was $1.94 B in 2025.

Net Income

Moderna annual net income was -$2.82 B in 2025.

Employees

Moderna annual employee count was 4,700 in 2025.

Revenue by Segment

Moderna’s revenue by segment: Product Sales: $3.30 B in 2025.

Revenue by Region

Moderna’s revenue by region: Europe: $53.00 M, Rest Of The World: $603.00 M and UNITED STATES: $1.20 B in 2025.

Executive Salary

Stéphane Bancel Chief Executive Officer, at Moderna, makes $19.93 M...

Revenue per Employee

Moderna revenue per employee was $413.62 K in 2025.

Profit per Employee

Moderna profit per employee was -$600.43 K in 2025.

Income Statement

Operating Income

Moderna annual operating income was -$3.07 B in 2025.

Research & Development

Moderna annual research & development expense was $3.13 B in 2025.

Tax Rate (%)

Moderna annual Tax Rate was -2.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Moderna annual total assets was $12.34 B in 2025.

Total Liabilities

Moderna annual total liabilities was $3.69 B in 2025.

Capital Expenditure

Moderna annual capital expenditures was -$192.00 M in 2025.

Ratios

Return on Equity (ROE)

Moderna annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Moderna annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Moderna annual debt to equity was 22.15% in 2025.

Profitability

Gross Profit Margin (%)

Moderna annual gross profit margin was 55.35% in 2025.

Operating Income Margin (%)

Moderna annual operating income margin was -158.13% in 2025.

Net Income Margin (%)

Moderna annual net income margin was -145.16% in 2025.

Earning Per Share

Moderna annual earning per share was -$7.25 in 2025.

EBITDA

Moderna annual EBITDA was -$3.07 B in 2025.

Free Cash Flow (FCF)

Moderna annual free cash flow(FCF) was -$2.07 B in 2025.

Valuation

Enterprise value

Moderna annual enterprise value was - in 2025.

Enterprise value to Revenue

Moderna annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Moderna annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

When was Moderna founded?

Moderna was founded on 2010, which makes the company 16 years old.

Sign up for free to view

Who is the CEO of Moderna?

Stéphane Bancel is the CEO of Moderna.

What industry and sector is Moderna in?

Moderna operates in the Biotechnology industry and the Healthcare sector.

What are Moderna's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0001682852
  • SIC (Standard Industrial Classification): 2836
  • ISIN (International Securities Identification Number): US60770K1079

Sign up for free to view

How many employees does Moderna have?

Moderna has 4,700 employees.

What is the revenue of Moderna?

In fiscal year 2025, Moderna generated a revenue of $1.94 Billion.

What is the net income of Moderna?

In fiscal year 2025, Moderna reported a net income of -$2.82 Billion.

What is Moderna's biggest product segment?

Product Sales is Moderna's biggest product segment, representing 100% of its total revenue.

When was Moderna listed on the stock exchange?

Moderna went public on Dec 7, 2018, through its Initial Public Offering (IPO), and it has been 7 years since then.

Sign up for free to view

What is the ticker symbol of Moderna, and where is it listed?

Moderna's ticker symbol is MRNA, and the company is listed on the NASDAQ stock market exchange.

What is Moderna's current stock price?

Moderna's current stock price is $57.01 as of Jul 24, 2026.

What is Moderna's market capitalization?

As of , Moderna's market cap is .

What is Moderna's ranking in the world?

Ranked #76among 2,823 companies based on market cap.

Who are the top competitors of Moderna?

Competitors of Moderna include Regeneron Pharmaceuticals, and more.

People Also Search For

Submit feedback to Bullfincher